Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAS1 | P04201 | 1/20 | 0.60 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 4/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3903957 | 0.93 | MAS1 (0.56) | MAS1AGTR2AGTR1 | |
| SCHEMBL4106426 | 0.93 | MAS1 (0.59) | MAS1AGTR2PPARGEDNRAAGTR1 | |
| SCHEMBL3908044 | 0.90 | MAS1 (0.69) | MAS1AGTR2AGTR1 | |
| SCHEMBL4110594 | 0.90 | MAS1 (0.58) | MAS1AGTR2PPARGEDNRAAGTR1 | |
| SCHEMBL3915251 | 0.87 | MAS1 (0.69) | MAS1AGTR2AGTR1 | |
| SCHEMBL4099345 | 0.86 | MAS1 (0.66) | MAS1AGTR2AGTR1 | |
| SCHEMBL7382680 | 0.85 | MAS1 (0.47) | MAS1AGTR2EDNRAAGTR1 | |
| SCHEMBL3909393 | 0.85 | MAS1 (0.65) | MAS1AGTR2AGTR1 | |
| SCHEMBL3975298 | 0.85 | AGTR2 (0.48) | MAS1AGTR2AGTR1 | |
| SCHEMBL1334134 | 0.85 | MAS1 (0.74) | MAS1AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1185527-B1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA GMBH (DE) | 2005-07-27 | — | — | EP | claimed |
| JP-2002544130-A | — | — | 2002-12-24 | — | — | JP | claimed |
| US-20020077344-A1 | 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical prepartions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2002-06-20 | — | — | US | claimed |
| EP-1185527-A1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2002-03-13 | — | — | EP | claimed |
| US-20010018449-A1 | 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2001-08-30 | — | — | US | claimed |
| US-6235766-B1 | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-22 | — | — | US | claimed |
| WO-2000068226-A1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-16 | — | — | WO | claimed |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | CAPACITY BIO INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | Capacity Bio, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| CN-117120417-A | Methods and agents for stimulating mitochondrial turnover to treat diseases | 容量生物公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. | 2022-07-28 | — | — | US | disclosed |
| EP-2018185-B1 | USE OF MAS-G-PROTEIN-COUPLED RECEPTOR AGONISTS IN THE TREATMENT OF THE METABOLIC SYNDROME, ITS COMPONENTS AND ITS COMPLICATIONS | UNIV MINAS GERAIS (BR) | 2016-08-31 | — | — | EP | disclosed |
| US-8586054-B2 | Method for modulating, treating and/or preventing metabolic syndrome using MAS-G-protein-coupled receptor agonists | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2013-11-19 | — | — | US | disclosed |
| EP-1185527-B1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA GMBH (DE) | 2005-07-27 | — | — | EP | disclosed |
| US-6429222-B2 | HYPOTENSIVE AGENT, ENDOTHELIAL DAMAGE, ARTERIOSCLEROSIS, ANTIDIABETIC AGENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-08-06 | — | — | US | disclosed |
| US-20020077344-A1 | 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical prepartions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2002-06-20 | — | — | US | disclosed |
| EP-1185527-A1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2002-03-13 | — | — | EP | disclosed |
| US-20010018449-A1 | 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2001-08-30 | — | — | US | disclosed |
| US-6235766-B1 | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-22 | — | — | US | disclosed |
| WO-2000068226-A1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | NLN, MAVS, PINK1 | MAS1 266/4885AGTR2 337/4885PPARG 222/4885 |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | NLN, MAVS, PINK1 | MAS1 266/4885AGTR2 337/4885PPARG 222/4885 |
| US-20010018449-A1 | 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical preparations comprising them | AGTR1, NPR1, EDNRB | MAS1 362/4885AGTR2 7/4885PPARG 1430/4885 |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | MDH2, NLN, PINK1 | MAS1 911/4885AGTR2 1203/4885PPARG 507/4885 |
| US-20020077344-A1 | 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical prepartions comprising them | AGTR1, NPR1, EDNRB | MAS1 427/4885AGTR2 8/4885PPARG 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.